Evidence map›Paper›PMID 29492470›Full record

ArticleJournal of scleroderma and related disorders

Systemic Sclerosis Trial Design Moving Forward.

Sindhu R Johnson, Dinesh Khanna, Yannick Allanore, Marco Matucci-Cerinic, Daniel E Furst

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of scleroderma and related disorders. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. The N-of-1 Trials and where to use them in Rheumatology.Mediterranean journal of rheumatology · 2025
    Review
  3. Advanced Autoantibody Testing in Systemic Sclerosis.Diagnostics (Basel, Switzerland) · 2023
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sindhu R JohnsonToronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, Department of Medicine; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
Dinesh KhannaDivision of Rheumatology, University of Michigan Scleroderma Program, Ann Arbor, MI, USA.
Yannick AllanoreRheumatology A Department, Paris Descartes University, Cochin Hospital, Paris, France.
Marco Matucci-CerinicDepartment of Rheumatology AVC, Department of BioMedicine, Division of Rheumatology AOUC, Department of Medicine & Denothecentre, University of Florence, Firenze, Italy.
Daniel E FurstCarl M Pearson Professor of Rheumatology, Division of Rheumatology, David Geffen School of Medicine, University of California Los Angeles, California, USA.

Funding

Outcomes Research in Rheumatic DiseasesK24AR063120 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KHANNA, DINESH · 2012 to 2022
$1.6M
NIAMS NIH HHS K24 AR063120
6 · The paper itself

Abstract

The 2013 ACR-EULAR classification criteria for systemic sclerosis (SSc) have shifted the construct of SSc. The new reality is that patients recruited for trials may not be so severe and not so advanced. We can now look for therapeutics that might stop disease evolution and/or prevent organ involvement. This article highlights recent advances in research methodology, and broadens the potential range of design and analytic considerations when planning a SSc trial.

Indexed as

Bayesiancross-over trialenriched enrolment randomized withdrawal designrandomized controlled trialsrandomized placebo phase designsclerodermaSystemic sclerosis

Identifiers

PMID29492470
PMCPMC5826575

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.